Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Li, Luyuan ^a,b   Paz, Ana C ^a,b   Wilky, Breelyn A ^a,b   Johnson, Britt ^a   Galoian, Karina ^a   Rosenberg, Andrew ^a   Hu, Guozhi ^a,b   Tinoco, Gabriel ^a,b   Bodamer, Olaf ^a   Trent, Jonathan C ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; AGI 5198; ANTINEOPLASTIC AGENT; ISOCITRATE DEHYDROGENASE 1; ONCOMETABOLITE 2 HYDROXYGLUTARATE; TUMOR MARKER; UNCLASSIFIED DRUG; AGI-5198; ALPHA-HYDROXYGLUTARATE; BENZENEACETAMIDE DERIVATIVE; ENZYME INHIBITOR; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; ISOCITRATE DEHYDROGENASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARTILAGE CELL; CELL CYCLE PHASE; CELL MIGRATION; CHONDROSARCOMA CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; ANTAGONISTS AND INHIBITORS; CHONDROCYTE; CHONDROSARCOMA; DRUG EFFECTS; GENETICS; METABOLISM; MISSENSE MUTATION; TUMOR CELL LINE;

APOPTOSIS; BENZENEACETAMIDES; CELL LINE, TUMOR; CHONDROCYTES; CHONDROSARCOMA; ENZYME INHIBITORS; GLUTARATES; HUMANS; IMIDAZOLES; ISOCITRATE DEHYDROGENASE; MUTATION, MISSENSE;

EID: 84947483826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133813     Document Type: Article

References (43)

1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. The Journal of pathology. 2011; 224(3):334-43. doi: 10.1002/path.2913 PMID: 21598255.
2. Jamil N, Howie S, Salter DM. Therapeutic molecular targets in human chondrosarcoma. International journal of experimental pathology. 2010; 91(5):387-93. doi: 10.1111/j.1365-2613.2010.00749.x PMID: 21078112; PubMed Central PMCID: PMC3003836.
3. Schaap FG, French PJ, Bovee JV. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. Advances in anatomic pathology. 2013; 20(1):32-8. doi: 10.1097/PAP.0b013e31827b654d PMID: 23232569.
4. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain tumor pathology. 2012; 29 (3):131-9. doi: 10.1007/s10014-012-0090-4 PMID: 22399191.
5. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American journal of pathology. 2009; 174(4):1149-53. doi: 10.2353/ajpath.2009.080958 PMID: 19246647; PubMed Central PMCID: PMC2671348.
6. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009; 360(8):765-73. doi: 10.1056/NEJMoa0808710 PMID: 19228619; PubMed Central PMCID: PMC2820383.
7. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010; 116(12):2122-6. doi: 10.1182/blood-2009-11-250878 PMID: 20538800.
8. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. The New England journal of medicine. 2010; 362(4):369-70. doi: 10.1056/NEJMc0910063 PMID: 20107228.
9. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 2010; 24 (5):909-13. doi: 10.1038/leu.2010.56 PMID: 20376086; PubMed Central PMCID: PMC2945692.
10. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and biophysical research communications. 2010; 393(3):555-9. doi: 10.1016/j.bbrc.2010.02.095 PMID: 20171178; PubMed Central PMCID: PMC2838977.
11. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. The oncologist. 2014; 19(6):602-7. doi: 10.1634/theoncologist.2013-0417 PMID: 24760710; PubMed Central PMCID: PMC4041671.
12. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. International journal of cancer Journal international du cancer. 2009; 125(2):353-5. doi: 10.1002/ijc.24379 PMID: 19378339.
13. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature genetics. 2011; 43 (12):1262-5. doi: 10.1038/ng.994 PMID: 22057236.
14. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature genetics. 2011; 43(12):1256-61. doi: 10.1038/ng.1004 PMID: 22057234; PubMed Central PMCID: PMC3427908.
15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta neuropathologica. 2008; 116(6):597-602. doi: 10.1007/s00401-008-0455-2 PMID: 18985363.
16. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. doi: 10.1038/nature08617 PMID: 19935646; PubMed Central PMCID: PMC2818760.
17. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of experimental medicine. 2010; 207(2):339-44. doi: 10.1084/jem.20092506 PMID: 20142433; PubMed Central PMCID: PMC2822606.
18. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell. 2010; 17(3):225-34. doi: 10.1016/j.ccr.2010.01.020 PMID: 20171147; PubMed Central PMCID: PMC2849316.
19. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010; 29(49):6409-17. doi: 10.1038/onc.2010.444 PMID: 20972461.
20. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. Journal of inherited metabolic disease. 2012; 35(4):571-87. doi: 10.1007/s10545-012-9462-5 PMID: 22391998; PubMed Central PMCID: PMC3388262.
21. Ma S, Jiang B, Deng W, Gu ZK, Wu FZ, Li T, et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget. 2015. PMID: 25825982.
22. Nyhan WL, Shelton GD, Jakobs C, Holmes B, Bowe C, Curry CJ, et al. D-2-hydroxyglutaric aciduria. Journal of child neurology. 1995; 10(2):137-42. PMID: 7782605.
23. Van Schaftingen E, Rzem R, Veiga-da-Cunha ML. -2-Hydroxyglutaric aciduria, a disorder of metabolite repair. Journal of inherited metabolic disease. 2009; 32(2):135-42. doi: 10.1007/s10545-008-1042-3 PMID: 19020988.
24. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012; 120(23):4649-52. doi: 10.1182/blood-2012-06-438267 PMID: 23074281.
25. Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. Journal of neuro-oncology. 2009; 91(2):233-6. doi: 10.1007/s11060-008-9706-2 PMID: 18931888.
26. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010; 18(6):553-67. doi: 10.1016/j.ccr.2010.11.015 PMID: 21130701; PubMed Central PMCID: PMC4105845.
27. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell. 2011; 19(1):17-30. doi: 10.1016/j.ccr.2010.12.014 PMID: 21251613; PubMed Central PMCID: PMC3229304.
28. Putiri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clinical epigenetics. 2011; 2 (2):299-314. doi: 10.1007/s13148-010-0017-z PMID: 21927626; PubMed Central PMCID: PMC3172155.
29. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes & development. 2011; 25 (10):1010-22. doi: 10.1101/gad.2037511 PMID: 21576262; PubMed Central PMCID: PMC3093116.
30. Waterfall JJ, Killian JK, Meltzer PS. The role of mutation of metabolism-related genes in genomic hypermethylation. Biochemical and biophysical research communications. 2014; 455(1-2):16-23. doi: 10.1016/j.bbrc.2014.08.003 PMID: 25111818.
31. Cairns RA, Harris I, McCracken S, Mak TW. Cancer cell metabolism. Cold Spring Harbor symposia on quantitative biology. 2011; 76:299-311. doi: 10.1101/sqb.2011.76.012856 PMID: 22156302.
32. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO reports. 2011; 12(5):463-9. doi: 10.1038/embor.2011.43 PMID: 21460794; PubMed Central PMCID: PMC3090014.
33. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-83. doi: 10.1038/nature10866 PMID: 22343889; PubMed Central PMCID: PMC3351699.
34. Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE, et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nature communications. 2013; 4:2166. doi: 10.1038/ncomms3166 PMID: 23863747; PubMed Central PMCID: PMC3759038.
35. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology. 2005; 7(2):134-53. doi: 10.1215/S1152851704001115 PMID: 15831232; PubMed Central PMCID: PMC1871894.
36. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: new insights and promises for the future. JAMA neurology. 2014; 71(10):1319-25. doi: 10.1001/jamaneurol.2014.1205 PMID: 25155243.
37. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324(5924):261-5. doi: 10.1126/science.1170944 PMID: 19359588; PubMed Central PMCID: PMC3251015.
38. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. doi: 10.1126/science.1236062 PMID: 23558169; PubMed Central PMCID: PMC3985613.
39. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA. Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clinical orthopaedics and related research. 2000;(376:):291-303. PMID: 10906887.
40. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974; 33(4):1027-33. PMID: 4132053.
41. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. The Journal of pathology. 2004; 202(3):367-74. doi: 10.1002/path.1527 PMID: 14991903.
42. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015; 125 (2):296-303. doi: 10.1182/blood-2013-10-533604 PMID: 25398940; PubMed Central PMCID: PMC4295919.
43. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012; 488(7413):656-9. doi: 10.1038/nature11323 PMID: 22763442; PubMed Central PMCID: PMC4005896.